Influence of a Medicinal Cannabinoid Agonist on Responses to Food Images and Food Intake

Influence of a Medicinal Cannabinoid Agonist on Behavioural Responses to Food Images and Food Intake: Role of Gut Peptides

Status

Active, not recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02310347

Enrollment

Registered

2014-12-08

Start date

2014-12-31

Completion date

2025-10-31

Last updated

2024-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Appetite Regulation

Brief summary

The purpose of this study is to examine the influence of a medicinal cannabinoid agonist versus placebo on behavioural and gut peptide responses to food images and food intake.

Interventions

DRUGdronabinol

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

For healthy volunteers: 1. 20 ≤ BMI ≤ 25 2. Age 18-60 3. Right handed 4. Stable body weight for at least 3 consecutive months at start of study and no history of behavioural, therapeutic or surgical treatment aiming at or leading to weight loss/gain For obese subjects: 1. BMI \> 30 2. Age 18-60 3. Right handed 4. Stable body weight for at least 3 consecutive months at start of the study and no behavioural, therapeutic or surgical treatment aiming at or leading to weight loss/gain for at least 3 consecutive months For FD patients: 1. FD diagnosis according to 'Rome III' criteria 2. Age 18-60 3. Right handed 4. 5% weight loss since onset of symptoms

Exclusion criteria

1. Medical conditions (current or history): * Abdominal/thoracic surgery except appendectomy * Gastrointestinal, endocrine (especially diabetes), or neurological diseases * Cardiovascular, respiratory, renal or urinary diseases * Hypertension * Food or drug allergies * Head trauma with loss of consciousness 2. Psychiatric disorders: * Eating disorders * Psychotic disorders * Major depressive disorder * Somatoform disorder 3. Medication use: * No history of cannabis use or any other drug of abuse for at least 12 months prior to the study * All medication except oral contraception; 4. Known allergy to dronabinol and/or sesam oil 5. Pregnancy, plans to conceive or refusal to take adequate precaution to avoid pregnancy 6. Subjects who refuse to abstain from driving during the study

Design outcomes

Primary

Measure	Time frame	Description
Behavioural responses to food images and food intake	2 years	Scores on Visual Analogue Scales
Gut peptide responses	2 years	Concentrations of gut peptide levels will be determined using radioimmunoassays

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026